Dynavax Technologies Corp. (NASDAQ:DVAX) shares saw strong trading volume on Thursday . 1,119,899 shares were traded during trading, an increase of 74% from the previous session’s volume of 643,472 shares.The stock last traded at $16.07 and had previously closed at $15.72.

Several equities research analysts recently weighed in on the company. Zacks Investment Research raised Dynavax Technologies Corp. from a “sell” rating to a “hold” rating in a report on Monday, June 27th. Cowen and Company reaffirmed a “buy” rating and set a $60.00 price target on shares of Dynavax Technologies Corp. in a report on Thursday, April 28th. Royal Bank Of Canada downgraded Dynavax Technologies Corp. from an “outperform” rating to a “sector perform” rating and decreased their price target for the stock from $48.00 to $17.00 in a report on Wednesday, April 27th. Finally, JPMorgan Chase & Co. cut Dynavax Technologies Corp. from an “overweight” rating to a “neutral” rating and cut their price objective for the stock from $29.00 to $22.00 in a research report on Wednesday, April 27th. One analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $32.20.

The firm’s market capitalization is $618.23 million. The stock has a 50-day moving average of $15.10 and a 200-day moving average of $17.41.

Dynavax Technologies Corp. (NASDAQ:DVAX) last issued its quarterly earnings results on Friday, August 5th. The biopharmaceutical company reported ($0.75) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.68) by $0.07. The firm earned $2.65 million during the quarter, compared to analyst estimates of $1.58 million. The company’s revenue was up 70.8% on a year-over-year basis. During the same period last year, the business earned ($0.80) EPS. On average, equities analysts expect that Dynavax Technologies Corp. will post ($2.96) EPS for the current fiscal year.

In other news, CEO Eddie Gray purchased 2,750 shares of the stock in a transaction dated Friday, May 20th. The stock was acquired at an average cost of $15.57 per share, for a total transaction of $42,817.50. Following the acquisition, the chief executive officer now owns 5,050 shares of the company’s stock, valued at $78,628.50. The acquisition was disclosed in a filing with the SEC, which is available at this link.

A hedge fund recently raised its stake in Dynavax Technologies Corp. stock. Swiss National Bank boosted its position in shares of Dynavax Technologies Corp. (NASDAQ:DVAX) by 5.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 48,528 shares of the biopharmaceutical company’s stock after buying an additional 2,600 shares during the period. Swiss National Bank owned about 0.13% of Dynavax Technologies Corp. worth $1,172,000 as of its most recent filing with the SEC.

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.